BrightPath Biotherapeutics Co., Ltd.

Cancer Immunotherapy

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno­therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials,immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.

電話アイコン +81-3-5840-7697
メールアイコン irpr@brightpathbio.com
お問い合わせアイコン https://www.brightpathbio.com/english/contact/index.html

LIC

Drug Discovery/Drug Discovery Support